Aisling Capital Investor
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
.jpg)
.jpg)
Technology:
Cell_Therapies
Industry:
Longevity Industry 2022
Headquarters:
New York, New York, United States
Founded Date:
2000-01-01
Employees Number:
11-50
Funding Status:
Active
Investor Type:
Private Equity Firm
Investment Stage:
Debt, Early Stage Venture, Late Stage Venture, Private Equity
Number Of Exits:
58
Acquisitions Number:
58
Estimated Revenue:
$1M to $10M
Register and Claim Ownership